expect follow pre-
follow pre-announc
recent discuss
manag lower sale earn outlook follow
disappoint sale report organ miss street
estim month rais outlook year posit
print expect new ceo chri barri want set achiev bar
one compani exceed look lower
overal organ growth expect due tougher comp
slow ou growth expect compani guid organ
sale growth deliv guidanc februari earn
call lower top-lin also expect less meaning oper leverag
model y/i oper margin expans versu previous
lower ep estim street
continu see set beyond challeng without
meaning improv global spine market unlik view
and/or competit robot offer remain sidelin
expect guid organ sale growth
februari earn call healthcar confer ceo barri
said compani want set appropri expect interpret
mean lower street low enough bar would allow
compani re-establish beat rais cultur follow mix top-lin
perform soft rang step
expect head healthcar confer pre-
announc result januari model come organ sale
growth previous street
remind post organ growth pro-
forma comp us spinal hardwar grow versu
guid us surgic support versu guid
in-lin expect
look growth segment forecast us spinal
hardwar organ growth us surgic support organ growth
biolog growth vs contribut puls less
ray organ growth manag continu
forecast ou growth smaller base us level well
exit
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
us spine market may stabil back half year
show sign recov level flat growth new norm
insur continu push back spinal procedur price pressur
intensifi continu find difficult construct compani
exposur market dont see meaning recoveri come
 model lower degre oper margin
expans slower top-lin growth organ growth forecast move
also moder expect around gross
oper margin expans year gross margin front model
y/i improv versu previous
captur gross margin expans move west carrolton
compani invest part busi lower gross margin
lower total gross margin expans oper margin move
forecast y/i improv
confer translat ep previous
street view street margin assumpt
aggress like come lower sale base expect street
estim come follow earn call commentari
invest thesi valuat risk
impress new ceo chri barri vision
think turnaround take time remain sidelin
downgrad share neutral june link note chang view
predic us spine market get structur challeng
face increas price pressur greater scrutini procedur
reimburs payor head continu view spine one
weaker end-market med-tech make challeng get
construct share compani complet expos end-
market add ceo barri also need drive revers oper margin
trend contract expans rebuild corpor cultur high
level turnov senior manag level past year
confid mr barri right ship view share trade
ev/sal price-to-earnings appropri valu near/mid-term base mid-
single-digit organ sale growth likelihood downward margin estim
revis incom ceo chri barri may tri reset bar
decemb price target valu share ev/sal multipl
sale forecast valuat level line current ntm multipl
select comp group moder growth smid-cap med-tech name
risk rate price
upsid risk rate includ recoveri growth us spine market
acceler share loss top player johnson johnson
return growth nuvas biolog portfolio
downsid risk rate includ signific declin spinal fusion
procedur volum result new restrict impos insur and/or chang
afford act poor execut new product launch
intern expans increas competit problem integr
acquir busi execut challeng achiev margin expans
inc summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end dec o/w
analyst certif author name within report research analyst unless otherwis specifi research analyst
denot ac cover report certifi multipl research analyst primarili respons report
research analyst denot ac cover within document individu certifi respect secur issuer
research analyst cover research view express report accur reflect person view
subject secur issuer part research analyst compens
directli indirectli relat specif recommend view express research analyst report korea-
base research analyst list front cover also certifi per kofia requir analysi made good faith
view reflect opinion without undu influenc intervent
